Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 6, 2026, Cryo-Cell International, Inc. (the "Company”) received a written notice from NYSE Regulation stating that it had accepted the Company’s plan to regain compliance with the continued listing standards of the NYSE American LLC ("NYSE American"). As previously disclosed, the Company submitted a compliance plan to NYSE American on April 8, 2026. NYSE Regulation accepted the plan and…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which wi…

Other Events. Cryo-Cell International, Inc. ("Cryo-Cell") will not declare a quarterly cash dividend for the fourth quarter of fiscal 2025. Cryo-Cell may or may not pay a dividend in future periods, and any future decisions regarding dividend declarations will be based on a variety of factors, including financial performance, capital requirements, and strategic priorities. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this repor…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (a) The information included in

Entry into a Material Definitive Agreement. As previously disclosed, on July 18, 2022, Cryo-Cell International, Inc. (the “Company”) entered into a Credit Agreement (“Credit Agreement”) with Susser Bank, a Texas state bank (“Susser”), as administrative agent on behalf of itself and the other lenders (collectively, the “Lenders”) for (i) an unsecured revolving line of credit in an aggregate principal amount of up to $10,000,000 (the “RCF”); and (ii) a term loan facility in an original principa…

Termination of a Material Definitive Agreement. Cryo-Cell International, Inc. (“Cryo-Cell”) has received from Duke University ("Duke") a notice of termination as of May 17, 2025, of the Patent and Technology License Agreement between Cryo-Cell and Duke dated effective as of February 23, 2021 (as amended, the "Duke License Agreement"). As previously disclosed, pursuant to the Duke License Agreement, Duke granted to Cryo-Cell an exclusive license to make, have made, use, import, offer for sale,…

Other Events. On May 7, 2025, as a result of the current economic environment and other capital allocation alternatives, the Board of Directors of Cryo-Cell International, Inc. ("Cryo-Cell") declared a reduced, quarterly cash dividend of $0.15 per share of common stock to be paid to its shareholders of record as of the close of business on May 21, 2025. The dividend is expected to be paid on May 30, 2025. .

Other Events. On October 29, 2024 the Board of Directors of Cryo-Cell International, Inc. ("Cryo-Cell") declared a cash dividend of $0.25 per share of common stock to be paid to its shareholders of record as of the close of business on November 15, 2024 and is expected to be paid on November 29, 2024. .

Results of Operations and Financial Condition. On October 15, 2024, the Company issued a press release announcing its financial results for the three and nine months ended August 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The press release may contain hypertext links to information on the Company’s website. The information on the Company’s website is not incorporated by reference into this Curr…

Regulation FD Disclosure. On March 25, 2024, Cryo-Cell International, Inc. ("Company" or "Cryo-Cell") issued a press release announcing plans to spin off its newly formed subsidiary, Celle Corp., to the Cryo-Cell shareholders and to explore all strategic alternatives for Cryo-Cell (post spin-off) to maximize shareholder value, including, but not limited to, equity and/or debt financings and/or the possible sale or merger of the company . A copy of the press release is attached hereto as Exhib…

Entry into a Material Definitive Agreement. On February 17, 2023, Cryo-Cell International, Inc. ("Company") entered into a Second Amendment to the License Agreement (the “Second Amendment”) with Duke, as previously disclosed in the Company’s Form 10-K filed on February 28, 2023. The Second Amendment changes the license fee due to Duke. The final payment that was due on February 23, 2023 was removed and the license fee is paid in full. The Second Amendment added a new milestone payment upon FD…

New employment agreements were signed with the Co-Chief Executive Officers, including details on compensation and benefits.

Entry into a Material Definitive Agreement. On August 19, 2022 the Board of Directors of Cryo-Cell International, Inc. ("Cryo-Cell") declared a one-time, special cash dividend of $0.90 per share of common stock to be paid to its shareholders of record as of the close of business on September 2, 2022 and is expected to be paid on September 9, 2022. . SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its be…

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: July 22, 2022 By: /s/ David Portnoy David Portnoy, Chairman and Co-CEO

Entry into a Material Definitive Agreement. On July 18, 2022, Cryo-Cell International, Inc. (the “ Company ”) entered into a Credit Agreement (“ Agreement ”) with Susser Bank, a Texas state bank, as administrative agent (“ Susser ”) on behalf of itself and the other lenders (collectively, the “ Lenders ”) for (i) a revolving credit facility in an aggregate principal amount of up to $10,000,000 (the “ RCF ”); and (ii) a term loan facility in an original principal amount of $8,960,000 (the “ Te…

Entry into a Material Definitive Agreement. On March 14, 2022, Cryo-Cell International, Inc. ("Cryo-Cell", or "the Company") entered into a Purchase Agreement ("Agreement") with Scannell Properties #502, LLC ("Seller") to acquire a commercial office building and associated property that is under construction ("the Property") located at 857 S. Briggs Avenue, Durham County, Durham, North Carolina ("Land") Pursuant to the terms of the Agreement, the Company's obligation to close the acquisition…

Results of Operations and Financial Condition. On February 22, 2022, the Company issued a press release, along with a shareholder letter, announcing its financial results for the fiscal year ended November 30, 2021. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The press release may contain hypertext links to information on the Company’s website. The information on the Company’s website is not incorporated…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 19, 2022, Cryo-Cell International, Inc. (the "Company") received a written notice (the "Notice") from NASDAQ Stock Market LLC ("Nasdaq") that the Company's audit committee is comprised of two independent board members, and no longer complies with Nasdaq's audit committee requirement that the audit committee be comprised of at lease three independent board members as set forth in Lis…

director — Brian Sheehy: Mr. Sheehy resigned as a director of the Company.

Results of Operations and Financial Condition. On October 15, 2021, Cryo-Cell International, Inc. (the "Registrant") issued the attached Press Release reporting on financial results for the three months ended August 31, 2021. The press release giving details associated with the Registrant's earnings is attached as Exhibit 99.1 to this report. The information included in Exhibit 99.1 is considered to be "furnished" under the Securities Exchange Act of 1934.

Director — George Gaines, Jonathan Wheeler, MD: Two directors resigned and were replaced by new appointees.

Chief Information Officer — Oleg Mikulinsky: The company entered into a new employment agreement with the Chief Information Officer.

Results of Operations and Financial Condition. On July 15, 2021, Cryo-Cell International, Inc. (the "Registrant") issued the attached Press Release reporting on financial results for the three months ended May 31, 2021. The press release giving details associated with the Registrant's earnings is attached as Exhibit 99.1 to this report. The information included in Exhibit 99.1 is considered to be "furnished" under the Securities Exchange Act of 1934.

New employment agreements were signed with the Co-Chief Executive Officers.

Results of Operations and Financial Condition. On April 14, 2021, Cryo-Cell International, Inc. (the "Registrant") issued the attached Press Release reporting on financial results for the three months ended February 28, 2021. The press release giving details associated with the Registrant's earnings is attached as Exhibit 99.1 to this report. The information included in Exhibit 99.1 is considered to be "furnished" under the Securities Exchange Act of 1934.